SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as the stock price hits new all-time highs, fueled by updates from the GTC event and potential new partnerships. The community is buzzing about the company's projected revenue growth and potential market cap, while also discussing whether the stock is overvalued. Trump's upcoming meeting with Jensen Huang and potential discussions about Nvidia's Blackwell chip with China are adding to the excitement.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending as discussions revolve around a rejected acquisition offer from Larvotto Resources and its potential impact. The community is analyzing whether the deal will be renegotiated or if UAMY will pursue alternative strategies, with some members emphasizing the company's strong fundamentals independent of the acquisition. Broader market factors, including potential easing of trade tensions with China and its impact on critical mineral supply chains, are also influencing the conversation.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending amid discussions about Gravity SUV deliveries, new partnerships, and the company's broader strategy in the EV market. While some celebrate recent achievements like winning the German Performance Car of the Year award, concerns persist around dilution, production targets, and the search for a permanent CEO, leading to mixed sentiment within the investment community.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid discussions surrounding a recent partnership with Nvidia, which the community believes could significantly impact the company's future revenue. Community members are actively debating the stock's valuation and potential for further growth, with some highlighting upcoming earnings as a key catalyst. Bullish sentiment is strong, with some traders predicting a continued climb.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending following news of Nvidia's $1 billion investment, sparking optimism around its role in AI-driven telecom and 6G technology. Community discussions revolve around potential breakouts and long-term growth, with some recalling Nokia's past prominence in the mobile phone market. The investment is seen as a validation of Nokia's pivot towards networking infrastructure and AI-related services, potentially positioning it as a key player in the future of telecommunications.

Another token of MartyrFi narrative to remember Tyke the Elephant. She was a female African bush elephant captured as a baby and shipped to the United States, where She was brutalised and instilled fear upon during the training for the circus, and shot 87 times whilst on the streets of Honolulu, Hawaii. She died of her injuries. She was forgotten but she will have a special place in our hearts forever  The token is built to remember and honour Tyke the elephant. The project is also built around being charitable towards elephants who may go through the same sort of abuse.

Tyke The Elephant

Tyke The Elephant ($TYKE) is gaining traction, particularly within the Phantom Wallet community, with many highlighting its potential. The community is discussing its 'moonshot vibes' and breakout potential, drawing comparison to established cryptocurrencies like Bitcoin and Solana. Bullish sentiment appears to be fueled by the token's perceived momentum.

The RealReal, Inc. is an online marketplace for consigned luxury goods, which engages in the consignment of luxury goods across multiple categories, including women's, men's, kids, jewelry, watches, home, and art. It sells pieces from designers such as Chanel, Christian Louboutin, Gucci, Hermes, Louis Vuitton, Prada, Celine, Jimmy Choo, Burberry, and Valentino. The company was founded by Julie Wainwright and Marcy Carmack on March 29, 2011 and is headquartered in San Francisco, CA.

Therealreal Inc

The RealReal (REAL) is trending amid mixed sentiment, with some users expressing concerns about the company's practices and financials, even alleging fraud related to consignment. Bullish investors point to potential benefits from tariffs, strong Q2 earnings results, and AI-driven efficiency gains while short-sellers express concerns about cash flow and debt, forecasting a price decline.

Based Chad

Based Chad is trending as community members highlight its strong accumulation and potential for a rally, especially with Coinbase executives showing interest. Discussions also center around the meme's cultural relevance and its presence on the Base network. Some users are noting the upcoming AAA video game.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending downward as the community debates the potential impact of prediction markets and recent NBA scandals on the sports betting landscape, with some seeing it as a buying opportunity due to the recent acquisition of Railbird and oversold conditions. Discussions include analyst ratings, potential for a short squeeze, and upcoming earnings report expectations. Some investors are concerned about increasing competition and regulatory headwinds.

Pump.fun

Pump.fun ($PUMP) is gaining traction, with the community rallying around the "We're All Gonna Make It" ($WAGMI) mantra, fostering a strong sense of shared success on the Solana ($SOL) blockchain. Discussions revolve around breaking resistance levels and potential breakouts, highlighting a bullish sentiment and anticipation for future growth. The community emphasizes its resilience and dedication, viewing $WAGMI not just as a ticker but as a commitment to long-term building.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CorMedix (CRMD) Surges 19.5%: Is This an Indication of Further Gains?

CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Johnson &amp; Johnson’s (J&amp;J) stock&nbsp;fell 0.4% in premarket trade on Tuesday as investors positioned ahead of the healthcare giant’s quarterly results due Tuesday, with focus on its medical devices business, drug pipeline, and tariff exposure.The company is expected to post revenue of $23.76 billion, nearly flat from last year's $23.74 billion, according to estimates from Koyfin. Adjusted EPS is expected to be $2.76, down from $2.77 a year ago. EBITDA is expected to come in 0.6% lower at $8.58 billion, while EBIT is expected to tick up 0.5% to $8 billion.J&amp;J shares trade near $190.90, close to their 12-month average price target of $187.49, implying limited near-term upside. Analysts maintain a broadly positive stance, with 10 rating it a ‘Buy,’ 11 a ‘Hold,’ and two a ‘Strong Buy.’In July, J&amp;J cut its tariff-related cost forecast for the year to $200 million, down from $400 million, citing lower-than-expected impact on its medical devices business after the Trump administration paused some China and EU duties. CFO Joe Wolk said the company absorbed the costs while still raising its profit outlook, describing the tariff effect as “minimal.”Growth in the medtech unit is expected to be a bright spot, driven by sales from cardiovascular products such as Varipulse and Trupulse, and Abiomed’s Impella heart pumps. J&amp;J said in July that robotic surgery and cardiovascular devices will be the key engines of growth for its medtech unit.Attention will also be on Carvykti, J&amp;J’s blood cancer therapy developed with Legend Biotech, which recently received a U.S. FDA label update adding a black box warning for a rare intestinal inflammation. Regulators said the therapy’s benefits still outweigh risks, highlighting longer patient survival versus standard treatments.In immunology, the company faces renewed pressure from biosimilar competition to its top-selling drug Stelara. To offset potential declines, J&amp;J has been pursuing acquisitions, including reported talks to acquire Protagonist Therapeutics, its partner on an oral therapy for plaque psoriasis and ulcerative colitis. A deal would add late-stage drug Rusfertide, seen as complementary to J&amp;J’s immunology and oncology portfolios.Legal overhangs persist after a $966 million jury verdict in California earlier this month tied to talc-related cancer claims, which J&amp;J plans to appeal. The company maintains&nbsp;that its products are safe and asbestos-free.On Stocktwits, retail sentiment for J&amp;J was ‘extremely bullish’ amid a&nbsp; 2,200% surge in 24-hour message volume.One user predicted that J&amp;J shares could climb to the $196–$200 range after earnings, while others speculated the biotech might announce an Altimmune acquisition during Tuesday’s earnings call.<stembedurl>https://stocktwits.com/Wenwenwenwenwenwen/message/632192878</stembedurl><stembedurl>https://stocktwits.com/Ad7777/message/632156784</stembedurl><stembedurl>https://stocktwits.com/namv/message/632137184</stembedurl><a href="https://stocktwits.com/symbol/JNJ">J&amp;J’s stock</a> has risen 35% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

JNJ beat third-quarter earnings estimates but lowered guidance for the year 

Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print

Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline.

Equity

Legend Biotech Corp. (LEGN) is reportedly considering a second listing outside of the US.According to a Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-05/legend-biotech-is-said-to-explore-second-listing-outside-of-us">report</a> on Friday, which cited unnamed people familiar with the matter, the New Jersey-headquartered company has discussed a second listing option with potential advisers. The company may list in Hong Kong, Singapore, or London, the report stated, while noting that a second listing could help boost the company's valuation, particularly if in Hong Kong.Hong Kong is currently emerging as a hub for biotech company listing, and the city’s Hang Seng Biotech Index has surged more than 100% this year, the report added.However, the company is only considering a second listing and may eventually decide against it, sources told Bloomberg.<a href="https://stocktwits.com/symbol/LEGN">LEGN shares</a> traded 3% higher at the time of writing. On Stocktwits, retail sentiment around LEGN stayed within ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.In August, Legend reported second-quarter (Q2) adjusted net income of $10.1 million, compared to an adjusted net loss of $2.5 million for the three months ended June 30, 2024, and total revenue of $255.1 million. The company ended June with cash and cash equivalents, as well as time deposits, totaling $1 billion.Legend, founded in 2014, is centered in the U.S. despite having roots in China and employs over 2,800 people. It's known for Carvykti, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets in collaboration with Johnson &amp; Johnson.LEGN stock is up 11% this year but down approximately 33% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/immunome-stock-rises-after-craig-hellum-initiates-coverage-with-26-dollar-price-target/chwIWHxRdqE">Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Legend Biotech Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Legend Biotech Considering Second Listing Outside US: Report

According to a Bloomberg report, the New Jersey-based company has discussed the option with potential advisers.

Company News for Aug 12, 2025

Companies In The News Are: MU, AAON, LEGN, FNV.

Key Inflation Data in Focus

Pre-Markets in Green, Inflation Data, Retail Sales, Q2 Earnings This Week

U.S. stock futures edged higher this morning after an impressive last week. 

Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?

Legend Biotech (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

These companies are most likely to surprise in real estate H1 earnings season

Investing.com -- Bernstein expects a mixed but potentially positive first-half earnings season for the European real estate sector, highlighting nine companies that could raise their guidance.

Deutsche Bank turns bullish on European real estate, lists top picks

Investing.com -- Deutsche Bank has adopted a more bullish view on the European real estate sector, pointing to a better economic outlook and increased preference for commercial property exposure.

European property stocks mixed amid downgrades & bond yield shifts

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Will Meta ($META) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Meta Platforms Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.07	--	--	N/A
Q2 '25	-$0.12	-$0.34	-195.59%	MISSED
Q1 '25	-$0.21	-$0.27	-28.31%	MISSED
Q4 '24	-$0.26	$0.07	126.72%	BEAT
Q3 '24	-$0.33	-$0.34	-3.11%	MISSED

LEGN
Legend Biotech

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest LEGN News

LEGNLegend Biotech